Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · IEX Real-Time Price · USD
15.29
-0.05 (-0.33%)
At close: Apr 24, 2024, 4:00 PM
15.28
-0.01 (-0.07%)
After-hours: Apr 24, 2024, 7:17 PM EDT
Y-mAbs Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Y-mAbs Therapeutics stock have an average target of 15.86, with a low estimate of 5.00 and a high estimate of 26. The average target predicts an increase of 3.73% from the current stock price of 15.29.
Analyst Consensus: Buy
* Price targets were last updated on Mar 4, 2024.
Analyst Ratings
The average analyst rating for YMAB stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 3 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 3 | 3 | 3 | 2 | 1 | 1 |
| Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 8 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains n/a | Strong Buy | Maintains | n/a | n/a | Mar 6, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $22 → $26 | Strong Buy | Maintains | $22 → $26 | +70.05% | Mar 4, 2024 |
| BMO Capital | BMO Capital | Buy Maintains $16 → $26 | Buy | Maintains | $16 → $26 | +70.05% | Mar 4, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $11 → $21 | Strong Buy | Maintains | $11 → $21 | +37.34% | Feb 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | -28.06% | Nov 15, 2023 |
Financial Forecast
Revenue This Year
100.27M
from 84.82M
Increased by 18.22%
Revenue Next Year
118.90M
from 100.27M
Increased by 18.58%
EPS This Year
-0.47
from -0.49
EPS Next Year
-0.35
from -0.47
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 110.3M | 139.7M | 137.8M | 153.2M | 260.3M |
| Avg | 100.3M | 118.9M | 127.3M | 145.0M | 233.8M |
| Low | 93.6M | 108.2M | 113.4M | 135.7M | 206.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 30.0% | 39.3% | 15.9% | 20.4% | 79.5% |
| Avg | 18.2% | 18.6% | 7.0% | 14.0% | 61.2% |
| Low | 10.3% | 7.9% | -4.6% | 6.6% | 42.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -0.36 | 0.02 | -0.92 | -0.33 |
| Avg | -0.47 | -0.35 | -1.05 | -0.32 |
| Low | -0.72 | -0.78 | -1.15 | -0.30 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | - |
| Avg | - | - | - | - |
| Low | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.